TNBC
Clinical trials for TNBC explained in plain language.
Never miss a new study
Get alerted when new TNBC trials appear
Sign up with your email to follow new studies for TNBC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug enters first human trials
Disease control Recruiting nowThis is an early-stage study to test the safety and initial effectiveness of a new drug called RO7502175 for people with advanced solid tumors that have spread or cannot be cured. The drug will be tested both by itself and combined with other approved cancer drugs. The main goals…
Matched conditions: TNBC
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
First-of-its-Kind pill targets Cancer's 'Guardian Gene' mutation
Disease control Recruiting nowThis study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…
Matched conditions: TNBC
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug combo aims to wipe out tough breast cancer before surgery
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called ivonescimab to standard chemotherapy before surgery is safe and more effective for people with early-stage triple-negative breast cancer (TNBC). About 34 participants will receive the drug combination for about …
Matched conditions: TNBC
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Smart cell therapy aims to target cancer while sparing healthy tissue
Disease control Recruiting nowThis study is testing a new type of cell therapy called A2B395 for adults with advanced solid tumors that have spread or returned. The therapy uses modified immune cells designed to specifically kill cancer cells while protecting the patient's healthy cells. The main goals are to…
Matched conditions: TNBC
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC